<SEC-DOCUMENT>0001193125-17-012746.txt : 20170119
<SEC-HEADER>0001193125-17-012746.hdr.sgml : 20170119
<ACCEPTANCE-DATETIME>20170119062432
ACCESSION NUMBER:		0001193125-17-012746
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20170119
DATE AS OF CHANGE:		20170119

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERON THERAPEUTICS, INC. /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-212784
		FILM NUMBER:		17534798

	BUSINESS ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AP PHARMA INC /DE/
		DATE OF NAME CHANGE:	20010511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERON THERAPEUTICS, INC. /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		4242 CAMPUS POINT COURT, SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AP PHARMA INC /DE/
		DATE OF NAME CHANGE:	20010511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>d328417dfwp.htm
<DESCRIPTION>FWP
<TEXT>
<HTML><HEAD>
<TITLE>FWP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Issuer Free Writing Prospectus </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 433 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration Statement No. <FONT STYLE="white-space:nowrap">333-212784</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>January&nbsp;19, 2017 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; text-indent:6%" ALIGN="center">


<IMG SRC="g328417g0119114729790.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Pricing Term Sheet </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This free writing prospectus relates to the public offering of the shares of common stock (the &#147;Common Stock&#148;) of Heron Therapeutics,
Inc. (the &#147;Issuer&#148;) and should be read together with the preliminary prospectus supplement dated January&nbsp;18, 2017 (the &#147;Preliminary Prospectus Supplement&#148;) to the prospectus dated July&nbsp;29, 2016 that is part of the
Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-212784)</FONT> filed with the Securities and Exchange Commission (&#147;SEC&#148;) before making a decision in connection
with an investment in this common stock. A copy of the Preliminary Prospectus Supplement can be accessed through the following link: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><A HREF="http://www.sec.gov/Archives/edgar/data/818033/000119312517012320/d326815d424b5.htm">
<U>http://www.sec.gov/Archives/edgar/data/818033/000119312517012320/d326815d424b5.htm</U> </A> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Offering Size:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">12,300,000 shares of Common Stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Public Offering Price:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$12.20 per share</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Option to purchase additional shares:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">1,845,000 additional shares of Common Stock offered by the Issuer (30 days)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Purchase&nbsp;by&nbsp;existing&nbsp;stockholder: </B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Tang Capital Partners, LP, an affiliate of Kevin Tang, the Chairman of the Issuer&#146;s Board of Directors, has agreed to purchase an aggregate of 2,459,016 shares of the Common Stock in this offering at the public offering
price. The underwriters will not receive any underwriting discounts or commissions with respect to any shares of Common Stock purchased by such stockholder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Proceeds, net of underwriting discounts, commissions and offering expenses:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Approximately $142.6&nbsp;million, or approximately $163.7&nbsp;million if the underwriters exercise their option to purchase additional shares of Common Stock in full</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Additional Information: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. has filed a registration statement (including a prospectus) on Form <FONT STYLE="white-space:nowrap">S-3</FONT> with
the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus supplement to the prospectus in such registration statement and other documents the issuer has filed with the SEC for more complete
information about Heron Therapeutics, Inc. and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will
arrange to send you the prospectus and the prospectus supplement if you request them by calling BofA Merrill Lynch at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-294-1322,</FONT></FONT></FONT> Cowen and Company, LLC at (631) <FONT STYLE="white-space:nowrap">274-2806</FONT> or Leerink Partners LLC at (800)
<FONT STYLE="white-space:nowrap">808-7525</FONT> ext. 6142. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g328417g0119114729790.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g328417g0119114729790.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !A /<# 2(  A$! Q$!_\0
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M<3$ X8]\'V!K(^%VLZ]K^F7E]K%Y]HC\P1P9B1,8')^4#/4?E74:_P"'-/\
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MY']POK5#^=?>CJJ*Y7_A8WA;_H(G_OR_^%7]+\7:%K$X@LM0C>8](V!4GZ9
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M.GS1%HX+8>;-(#CZ#\:[<-@J7U>4U)I_U^9X]7#5*6(5..TOOMU]"33] O\
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M * UM^1_QIU)TTH\S>RV%"E.\K);O<S?[<\ ?\]=%_[])_A1_;G@#_GKHO\
MWZ3_  K2_P"$(\,_] :V_(_XT?\ "$>&?^@-;?D?\:RYZ/>1I[.IVB9O]N>
M/^>NB_\ ?I/\*/[<\ #_ ):Z+_W[3_"M+_A"/#/_ $!K;\C_ (T?\(1X9_Z
MUM^1_P :.>CWD'LZG:)PNJZ]X>O/B-I]P]U9S:<EN5=FPT8/8>E=1_;G@#_G
MKHO_ 'Z3_"N8U'P[H\7Q5TW3DT^%;22V+/$ =I/K7<_\(1X9_P"@-;?D?\:V
MJSI)1U>QE3I5+R=EN9O]N> /^>NB_P#?I/\ "C^W/ '_ #UT7_OTG^%9?B7X
M66-V1>:&L=K=)SY+C,4F.Q]*S-&G\-1WJZ3XG\.V^F:B. [*?*E]P<\4*-*4
M>:+D_+J.U1.S21T_]N> /^>NB_\ ?I/\*Y3Q=>>'-0N],A\,I ^JFX4A[)-N
M%]\<5W@\%>&&4,NCVI!&00#S^M7;'P_I.DEI-/T^""4@X94Y_.HA7IP?-&[?
MF.="=2/+*UO0YG7?%&IW6KCPYX<5'OPH^TW3#*P^OXU-I_PZTY9/M6MSSZM>
MMRSSN=N?8>GUK-^%VR2?Q#-)S>&]99">H&3@?2O1:FK4=%^SIZ=WU94**J>_
M4U\NB*,.BZ5;)M@TVSC7T2!1_2H+SPUH=^A6YTJS?/\ %Y0#?F.:U:*YU4FG
M>YNZ<&K-(X*[\#WVALU[X0U&:WD'S-93/NBD]N?Z_F*UO"GBM/$EC<1SPFVU
M*T)2YMS_  GU'M_*NGKS:+;#\;[Q+3A9-/W7(7INP.O_ ([^==$9NM%J>Z5[
M_P"9A[)4I)T]$^G0R_ GA:UU_P )M>1S2V>IPW;B&[A.&7Y5P#ZCFNEM_%>I
M>'KE+#Q9!M0G;%J4*YC?_>]#57X.'=X+F/\ T^R?^@I7>75K;WMN]O=0I-"X
MPR.,@U>(K7JRC-75_FO0BAA^6FG#1_@_4:?LVI61 9)K>9>JG((JGH&G?V9I
M,5NR!9 6+>O4XKEKCPWK'A29KSPM,9[,G=)ILS9'_ #VK;\/>,=/UXFW^:UU
M!.)+2?Y74^WK6,H-0?([Q_K<W5G).2LSHJX#2V_XO)K"^EFO\DKOZ\[TEO\
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=HH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
